Roche's James Sabry inks his sec­ond AI deal in back-to-back pacts — this time part­ner­ing Genen­tech with Stan­ford spin­out Gen­e­sis Ther­a­peu­tics

Less than a week af­ter Roche joined forces with Dyno Ther­a­peu­tics to de­vel­op gene ther­a­pies us­ing ar­ti­fi­cial in­tel­li­gence, its gi­ant sub­sidiary Genen­tech is hop­ping on the AI band­wag­on with a dif­fer­ent play­er.

Genen­tech has inked a deal with Stan­ford spin­out Gen­e­sis Ther­a­peu­tics to har­ness its AI pow­er for drug de­vel­op­ment and dis­cov­ery. Gen­e­sis is get­ting an up­front pay­ment and mile­stones, but the com­pa­nies are keep­ing the de­tails un­der wraps for now. The Burlingame, CA-based biotech al­so stands to earn fu­ture roy­al­ties on any ap­proved Genen­tech drugs that come from the deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER